Given the constrained availability of data regarding SGLT2 inhibitors in individuals with heart failure and obstructive sleep apnea, our inclusion criteria encompassed studies involving these medications among patients with OSA and other conditions, e.g., diabetes, where more comprehensive data were obtained. This evidence concerns the gene SLC5A2 and diabetes mellitus.